A new wave of
potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, p. 24).
Not exact matches
With the
potential to affect such a diverse array of neurological ailments, many of which have no known
therapy, the hope is that an improved understanding of
immune - CNS interactions will bring to light new paradigms for preventing and treating neurological disease.
«Knowing that
immune cytokines can change pigment production in melanocytes, while also knowing that chronic inflammation has the
potential to increase the number of melanocytes, has clear implications for the design of future
therapies to address a set of common skin disorders,» says Dr. Krueger, director of Milstein Research Program and D. Martin Carter Professor in Clinical Investigation.
On the flipside, targeting this growth factor or BCL - 2 could reduce NK cell numbers and offer
potential therapies for
immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.
Still, the standard form of liver - targeted gene
therapy carries a range of
potential complications, including the risk of harmful mutations and of the body mounting an
immune response against the viral vectors used to carry the correct forms of the defective genes responsible for haemophilia.
They suggest allocating greater resources to research focused on
immune checkpoint
therapies and targeted / immunotherapy combination
therapies with «curative
potential.»
Dr. Martinez - Agosto noted, «Looking at the functionality of these genes and their effect on the
immune response has great
potential for accelerating the development of new targeted
therapies.»
Two teams of scientists suggest that activating
immune cells in fat can convert the tissue from a type of fat that stores energy to one that burns it, opening up
potential new
therapies for obesity and diabetes.
The results also indicate the KRAS - variant's
potential to identify people who will respond differently to
therapies that depend on the
immune response.
Her work - published in December 2007 - revealed genes involved in drug resistance and in evading the
immune system, giving researchers
potential targets for new
therapies and vaccines.
The
immune system underlies the pathophysiology of nearly every disease, yet
therapies that modulate immunity for clinical benefit have yet to reach their full
potential.
The data presented provide new insights on the
potential mechanism by which Seres» microbiome
therapies could improve the outcomes of cancer patients treated with
immune checkpoint inhibitors.
Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus groups, including checkpoint inhibitors, therapeutic vaccines, innate
immune stimulants, targeted
therapies, and many other promising treatments and technologies with high therapeutic
potential.
Together with his colleagues, he set to work building a better mouse model, one with human
immune cells that would make it possible to safely and reliably assess
potential vaccines and
therapies prior to human trials.
Although researchers are excited about the
potential to use CRISPR to create
therapies from people's own blood,
immune, and stem cells, thousands more genetic conditions affect everything else.
In an editorial published with the study, Viktor Grunwald, of Hannover Medical School, Germany, wrote «these antitumour activity findings indicate the
potential clinical benefit of targeted -
immune combinations and suggest that further studies are warranted to explore whether a first - line targeted -
immune combination might overcome the standard of sequential targeted and
immune therapies.»
Used with concomitant maintenance
immune suppression
therapy, the PEC - Direct product has the
potential of delivering a sustained, functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
Science continues to show the
potential for whole food concentrates and glandular
therapy to heal a variety of degenerative conditions and
immune system disorders.
Once the doctor has ruled out other
potential problems and treated any secondary skin or ear infections,
therapy can be guided toward treating with prescription medications, and using hyposensitization techniques which allow patients to slowly become «
immune» to their allergies.